Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.52 | 1.55 | -4.12 |
| FCF Yield | -193.52% | -19.43% | -17.43% | -9.63% |
| EV / EBITDA | -0.27 | -3.68 | -4.43 | -7.71 |
| Quality | ||||
| ROIC | -44.69% | -51.64% | -37.38% | -30.33% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.72 | 0.89 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 5.85% | 2.96% | -2.46% | 55.86% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 0.08 | 0.82 | 1.25 |
| Interest Coverage | 143.87 | 0.00 | 0.00 | -132.52 |
| Efficiency | ||||
| Inventory Turnover | 0.01 | 0.03 | 0.00 | 0.00 |
| Cash Conversion Cycle | 14,639.18 | 5,818.72 | -5,498.66 | -2,367.38 |